Tarsus Pharmaceuticals (TARS) Cash from Financing Activities (2019 - 2026)

Tarsus Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 99.12% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $8.0 million (down 95.6% YoY), while the FY2025 annual figure was $143.4 million, down 7.29% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $1.2 million, down from $2.3 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $136.6 million in Q1 2025, with the low at -$136000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is $2.9 million (2024), against an average of $30.8 million.
• Peak annual rise in Cash from Financing Activities reached 7473300.0% in 2022, while the deepest fall reached 281.33% in 2022.
• Tarsus Pharmaceuticals' Cash from Financing Activities stood at $264000.0 in 2022, then surged by 7384.85% to $19.8 million in 2023, then slumped by 85.19% to $2.9 million in 2024, then fell by 21.01% to $2.3 million in 2025, then plunged by 47.92% to $1.2 million in 2026.
• Business Quant data shows TARS's Cash from Financing Activities at $1.2 million in Q1 2026, $2.3 million in Q4 2025, and $2.6 million in Q3 2025.